Home > Drugs A – Z > Ipilimumab (By injection)

Ipilimumab (By injection)

Treats melanoma (skin cancer). Also helps prevent melanoma from coming back after surgical removal.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Ipilimumab injection is used to treat melanoma (a type of skin cancer) that has spread or cannot be removed by surgery. It is a monoclonal antibody that changes the immune system to help control the growth of cancer cells in the skin. Ipilimumab injection is also used to help prevent melanoma from coming back after surgical removal. This medicine is to be given only by or under the immediate… Read more
Brand names include
Yervoy
Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Ipilimumab (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of ipilimumab compared with dacarbazine as appropriate comparator therapy (ACT) in adult patients with advanced (unresectable or metastatic) melanoma who have not received prior therapy to treat advanced melanoma.

Ipilimumab -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of ipilimumab compared to best supportive care (BSC) as appropriate comparator therapy (ACT) in adult patients with advanced (unresectable or metastatic) melanoma, who have received prior therapy.

Addendum to Commission A13-44 (Ipilimumab, New Therapeutic Indication) [Internet]

On 11 March 2014 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-44 (benefit assessment of ipilimumab, new therapeutic indication).

See all (12)

Summaries for consumers

Nivolumab (Opdivo) for the treatment of melanoma: Treatment of melanoma with nivolumab (Opdivo) combined with ipilimumab (Yervoy)

In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of nivolumab (trade name: Opdivo) combined with ipilimumab (trade name: Yervoy) for people with advanced melanoma.The results of their assessment were different for the following three groups of patients:The manufacturer did not provide any suitable data on people who had previous treatment. So it remains unclear whether nivolumab combined with ipilimumab has any advantages or disadvantages for this group of people compared with individually tailored treatment.The manufacturer did not provide any suitable data related to how vemurafenib compares with nivolumab combined with ipilimumab used as a first treatment for people with a BRAF V600 mutation. So it remains unclear whether nivolumab combined with ipilimumab has any advantages or disadvantages for this group of people.The manufacturer provided one study related to how nivolumab plus ipilimumab as a first treatment compares with nivolumab alone for people without a BRAF V600 mutation. In this study, results from 429 people were available for analysis. Half of them had received treatment with nivolumab and ipilimumab, while the other half had used nivolumab only. Both groups received nivolumab at different doses during the first 12 weeks of the study. In this phase, those patients who had treatment with nivolumab alone received 3 mg of the drug per kilogram of bodyweight every two weeks. Those people who had treatment with nivolumab and ipilimumab received a much lower dose at 1 mg of nivolumab per kilogram of bodyweight every three weeks.The study involved patients without BRAF V600 mutation whose cancer had already spread (metastasized) at the time of diagnosis or who could not have surgery. Despite the advanced stage of their condition, the patients were in good general health. The following results were found:

Nivolumab (Opdivo) for the treatment of melanoma: Overview

Nivolumab (trade name: Opdivo) has been approved in Germany since June 2015 for the treatment of advanced melanoma in adults. Since May 2016, it has also been approved in combination with the drug ipilimumab.

Nivolumab (Opdivo) for the treatment of melanoma: Treatment of melanoma with nivolumab (Opdivo) only

In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether treatment with nivolumab (Opdivo) alone has an added benefit over the standard treatment for advanced melanoma.The results of their assessment were different for the following three groups of patients:The manufacturer did not provide any suitable data on people who used nivolumab after unsuccessful treatment. So it remains unclear whether nivolumab has any advantages or disadvantages for this group of people compared with individually tailored treatment.The manufacturer did not provide any suitable data related to how vemurafenib compares with nivolumab used as a first treatment for people with a BRAF V600 mutation. It therefore remains unclear whether nivolumab has any advantages or disadvantages for these people.The Institute analyzed the results of one study comparing nivolumab as a first treatment for people without a BRAF V600 mutation with the drugs dacarbazine and ipilimumab. 418 people took part in this study. Half of them were treated with the drug nivolumab, and the other half were given dacarbazine.The following results were found for patients without a BRAF V600 mutation who were treated for the first time.

See all (5)

PubMed Health Blog...

read all...